These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 25807427)
1. Protective effects of valsartan and benazepril combined with atorvastatin on cardiorenal syndrome in rats. Tang SY; Peng DF; Hu YJ; Chen J Eur Rev Med Pharmacol Sci; 2015; 19(5):759-66. PubMed ID: 25807427 [TBL] [Abstract][Full Text] [Related]
2. Comparison of valsartan and benazepril when combined with atorvastatin in protecting patients with early cardio-renal syndrome (CRS). Peng DF; Tang SY; Hu YJ; Chen J; Peng X; Huang Q Eur Rev Med Pharmacol Sci; 2015 Apr; 19(7):1264-71. PubMed ID: 25912588 [TBL] [Abstract][Full Text] [Related]
3. Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension. Ke YS; Tao YY; Yang H; Yu GH Acta Pharmacol Sin; 2003 Apr; 24(4):337-41. PubMed ID: 12676074 [TBL] [Abstract][Full Text] [Related]
4. Protective effects of naringenin in cardiorenal syndrome. Liu Y; An W; Gao A J Surg Res; 2016 Jun; 203(2):416-23. PubMed ID: 27363651 [TBL] [Abstract][Full Text] [Related]
5. Effect of combination of valsartan with benazepril on blood pressure and left ventricular hypertrophy in SHR. Ke YS; Cao H; Yang T Acta Pharmacol Sin; 2000 Nov; 21(11):1043-7. PubMed ID: 11501062 [TBL] [Abstract][Full Text] [Related]
6. [Mechanism of reversion of myocardial interstitial fibrosis in diabetic cardiomyopathy by valsartan]. Zhong M; Zhang Y; Miao Y; Li L; Gong HP; Ma X; Sun H; Zhang W Zhonghua Yi Xue Za Zhi; 2006 Jan; 86(4):232-6. PubMed ID: 16677501 [TBL] [Abstract][Full Text] [Related]
7. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. Ruilope LM; Aldigier JC; Ponticelli C; Oddou-Stock P; Botteri F; Mann JF J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548 [TBL] [Abstract][Full Text] [Related]
8. MicroRNA-208a Increases Myocardial Endoglin Expression and Myocardial Fibrosis in Acute Myocardial Infarction. Shyu KG; Wang BW; Cheng WP; Lo HM Can J Cardiol; 2015 May; 31(5):679-90. PubMed ID: 25936493 [TBL] [Abstract][Full Text] [Related]
9. [Activation of transforming growth factor-beta1/Smads signal pathway in diabetic cardiomyopathy and effects of valsartan thereon: experiment with rats]. Miao Y; Zhang W; Zhong M; Ma X; Qi TG; Sun H Zhonghua Yi Xue Za Zhi; 2007 Feb; 87(6):366-70. PubMed ID: 17456374 [TBL] [Abstract][Full Text] [Related]
10. [Mechanism of cardioprotection against ischemia/reperfusion injury by valsartan: an experiment with isolated rat hearts]. Zhang YJ; Bai XJ; Qi ZM; Wang HX Zhonghua Yi Xue Za Zhi; 2005 Dec; 85(47):3350-3. PubMed ID: 16409843 [TBL] [Abstract][Full Text] [Related]
11. Blockade of angiotensin converting enzyme but not of angiotensin AT1 receptors improves glucose tolerance. Chow L; De Gasparo M; Levens N Eur J Pharmacol; 1997 Jan; 319(1):77-83. PubMed ID: 9030901 [TBL] [Abstract][Full Text] [Related]
12. Protective effects of valsartan against cigarette smoke-induced left ventricular systolic dysfunction in rats. Zhou X; Li C; Xu W; Chen J Int J Cardiol; 2013 Aug; 167(3):677-80. PubMed ID: 22464480 [TBL] [Abstract][Full Text] [Related]
13. Qiliqiangxin Protects against Renal Injury in Rat with Cardiorenal Syndrome Type I through Regulating the Inflammatory and Oxidative Stress Signaling. Duan X; Yan F; Hu H; Liu H; Wu Q; Sun S; Ming X; Bu X; He Y; Zhu H Biol Pharm Bull; 2018; 41(8):1178-1185. PubMed ID: 30068867 [TBL] [Abstract][Full Text] [Related]
14. [Effects of valsartan, mycophenolate mofetil and their combined application on TRAIL and nuclear factor-kappaB expression in the kidneys of diabetic rats]. Chen B; Zhang Y; Liu G; Guan GJ; Hou XH; Li XG; Liu JL Zhonghua Yi Xue Za Zhi; 2008 Feb; 88(8):540-5. PubMed ID: 18649770 [TBL] [Abstract][Full Text] [Related]
15. Combined levosimendan and Sacubitril/Valsartan markedly protected the heart and kidney against cardiorenal syndrome in rat. Sung PH; Chai HT; Yang CC; Chiang JY; Chen CH; Chen YL; Yip HK Biomed Pharmacother; 2022 Apr; 148():112745. PubMed ID: 35202913 [TBL] [Abstract][Full Text] [Related]
16. Pathophysiological model of chronic heart failure complicated with renal failure caused by three-quarter nephrectomy and subcutaneous injection of isoprenaline. Peng DF; Tang SY; Hu YJ; Chen J; Yang L Exp Ther Med; 2013 Mar; 5(3):835-839. PubMed ID: 23403929 [TBL] [Abstract][Full Text] [Related]
17. [The diagnostic value of copeptin in the cardiorenal syndrome rats and the association with heart and kidney impairment]. Sheng XS; Ding MX; Guo FM; Yu ZP; Hua X; Lin L Zhonghua Nei Ke Za Zhi; 2018 Jul; 57(7):518-521. PubMed ID: 29996272 [TBL] [Abstract][Full Text] [Related]
18. Effects of the combined use of benazepril and valsartan on apoptosis in the kidney of rats with adriamycin-induced nephritic glomerulosclerosis. Han Z; Xing Y; Wang H; Liang X; Zhou J J Huazhong Univ Sci Technolog Med Sci; 2004; 24(3):254-8. PubMed ID: 15315341 [TBL] [Abstract][Full Text] [Related]
19. Effect of atorvastatin on serum oxidative stress and N-terminal brain natriuretic peptide expression in rats. Xu Y; Yang Y; Luo YQ Asian Pac J Trop Med; 2014 May; 7(5):398-401. PubMed ID: 25063069 [TBL] [Abstract][Full Text] [Related]
20. Contribution of different Nox homologues to cardiac remodeling in two-kidney two-clip renovascular hypertensive rats: effect of valsartan. Wang P; Tang F; Li R; Zhang H; Chen S; Liu P; Huang H Pharmacol Res; 2007 May; 55(5):408-17. PubMed ID: 17324585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]